Alternative first-line HIV regimen limits excess weight gain
Dolutegravir knocks down HIV faster than bictegravir
The untapped potential of CD8 cells
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Top 5 stories on HIV in Asia from IAS 2023
Immediate ART associated with fewer deaths in Thailand, but starting a week or two later may lead to less virological failure
Doravirine/islatravir just as effective as Biktarvy in previously untreated people
People with weakened immune systems still at risk of treatment failure, even with newer ART regimens
HIV controllers may be more susceptible to non-AIDS illnesses compared to people on HIV treatment
